Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273462 · ClinicalTrials.gov registry record · Phase 2
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
A Phase 2 study of Chronic Pain, sponsored by Navy Medical Center San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06273462 is a Phase 2 study of Chronic Pain that is actively recruiting participants, run by Navy Medical Center San Diego. The registered enrollment target is 80 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06273462, a Phase 2 study of Chronic Pain, is actively recruiting participants, sponsored by Navy Medical Center San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo. Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Palmitoylethanolamide 600mg twice a day
Study Locations (1)
California
- Naval Medical Center San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06273462
The ClinicalTrials.gov registry entry for NCT06273462 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (90% lower). The listed sponsor is Navy Medical Center San Diego, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06273462 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06273462 about?
NCT06273462 is a clinical study titled "Palmitoylethanolamide for Chronic Inflammatory Pain Conditions". The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their...
What is the current status of trial NCT06273462?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-08-05. Estimated completion is 2025-10-30.
What conditions does trial NCT06273462 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT06273462?
The interventions under investigation include: placebo (OTHER), Palmitoylethanolamide 600mg twice a day (DRUG).
Who is sponsoring clinical trial NCT06273462?
This trial is sponsored by Navy Medical Center San Diego, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273462 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.